Anyone know whether Epicentre 'an Illumina company' is discontinuing all 454 Nextera library products now that they are selling an updated Illumina version directly? Could not find any info on either site about it.
Unconfigured Ad
Collapse
X
-
The answer
From our sales rep: "I was able to confirm to day that this kit is being discontinued as of May 2012. The final decision was made yesterday and an email will be sent to all of the customer base within the next day or two. Regards..."
And probably the protocol is patented so no other company can take up the slack.
-
Nextera DNA Sample Prep Kits (Roche 454-Compatible) will be available for sale through Epicentre Customer Service until May 31, 2012, with final shipments required by June 30, 2012. This transition period will allow existing customers using these kits to complete ongoing projects without interruption.
Comment
Latest Articles
Collapse
-
by SEQadmin2
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...-
Channel: Articles
07-31-2026, 11:01 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 08-20-2026, 11:17 AM
|
0 responses
17 views
0 reactions
|
Last Post
by SEQadmin2
08-20-2026, 11:17 AM
|
||
|
Started by SEQadmin2, 08-18-2026, 10:05 AM
|
0 responses
26 views
0 reactions
|
Last Post
by SEQadmin2
08-18-2026, 10:05 AM
|
||
|
Started by SEQadmin2, 08-13-2026, 12:22 PM
|
0 responses
42 views
0 reactions
|
Last Post
by SEQadmin2
08-13-2026, 12:22 PM
|
||
|
Started by SEQadmin2, 08-11-2026, 10:35 AM
|
0 responses
33 views
0 reactions
|
Last Post
by SEQadmin2
08-11-2026, 10:35 AM
|
Comment